Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0015672 (fatigue)
 51,768 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Static and fatigue tests of the standard Orthofix unilateral external fixator (Orthofix SRL, Verona, Italy) were performed. Under similar fixation configurations, the Orthofix device offered higher bending stiffness in both directions, equal torsional stiffness, and lower axial stiffness when compared to the Hoffmann-Vidal quadrilateral frame with full pins. The bending resistance of the Orthofix ball joint was found to be proportional to its locking cam tightening torque. After applying 2 million loading cycles to the bone ends fixed by the device, the overall stiffness characteristics of the frame did not change significantly. Repetitive manual tightening and loosening of the ball joint caused abrasive wear on the cam and bushing surfaces. The locking position of the cam migrated for a mean of 45 degrees. After 50 cycles of tightening and bending to failure, the ball joint locking strength was reduced by 20% to 25%, but the stiffness did not change. Wear and stripping of the seat of the fixator body locking screw and the pin fixation screw threads were also noted. Based on the test results, the standard Orthofix device could be re-used, but certain fixator components must be inspected and replaced. The ball joint locking cam and fixation screws required periodic tightening during clinical application to prevent loss of frame stiffness under repetitive loading. Modifications of the fixator design are recommended to improve its mechanical performance.
 ...
PMID:Mechanical performance of the standard Orthofix external fixator. 340 6

Sarcalumenin is a Ca2+-binding protein located in the sarcoplasmic reticulum of striated muscle cells, the physiological function of which has not been fully determined yet. Using sarcalumenin knockout (sar(-/-)) mice, we showed that sar ablation altered store-operated Ca2+ entry (SOCE) and enhanced muscle fatigue resistance. Sar(-/-) mice fatigued less with treadmill exercise, and intact isolated soleus and extensor digitorum longus muscles from sar(-/-) mice were more resistant to intermittent fatiguing stimulation than those from wild-type mice. Enhanced SOCE was observed in the sar(-/-) muscles. Biochemical analysis revealed that sar(-/-) muscles contained significantly elevated expression of mitsugumin 29 (MG29), a synaptophysin-related membrane protein located in the triad junction of skeletal muscle. Because the ablation of mg29 has been shown to cause increased fatigability and dysfunction of SOCE, the enhanced SOCE activity seen in sar(-/-) muscle may be correlated with the increased expression of MG29. Our data suggest that systemic ablation of sarcalumenin caused enhanced resistance to muscle fatigue by compensatory changes in Ca2+ regulatory proteins that effect SOCE.
 ...
PMID:Enhanced resistance to fatigue and altered calcium handling properties of sarcalumenin knockout mice. 1599 45

Acromegaly is an insidious disorder characterized by excess secretion of growth hormone (GH) and elevated circulating levels of insulin-like growth factor-I (IGF-I), generally caused by a pituitary adenoma. It is a rare disease associated with an average 10-year reduction in life expectancy due to metabolic, cardiovascular, and cerebrovascular comorbidities and reduced quality of life caused by paresthesias, fatigue, osteoarthralgia, or bone fractures. In 2000, Cortina Consensus Conference established general criteria for diagnosis and biochemical control of acromegaly, which have been revised in recent years, adapting them to emerging clinical evidences as well as the evolving assay techniques. Authors have proposed a binary definition of cure for acromegaly, where both GH and IGF-I are important determinants: the former is more linked to the presence of residual adenomatous tissue, while the latter to the peripheral activity of the disease. Control of tumor growth and complications is also an essential goal of treatment. Surgical, medical, and radiotherapy approaches are all valid alternatives. The surgical option is, however, unsuccessful in about 50% of patients. Somatostatin analogs (SRLs), octreotide LAR, and lanreotide ATG can inhibit cell growth, besides their beneficial effects on GH hypersecretion and on most comorbidities. Pasireotide is a new multireceptor-targeted SRL with reported superior biochemical efficacy to octreotide, due to higher affinity for SSTR-5, but potentially causing detrimental effects on glucose homeostasis. Pegvisomant could be a valid choice in all patients resistant to SRLs. It is a competitive GH antagonist, which efficaciously blocks IGF-I production, inhibiting the dimerization of GH receptor. Normal IGF-I levels represent, therefore, its only relevant efficacy endpoint, while only few cases of tumor growth on pegvisomant have been reported, so far.
...
PMID:The Modern Criteria for Medical Management of Acromegaly. 2694 Mar 87